Download Handbook of Pharmaceutical Manufacturing Formulations - by Sarfaraz K. Niazi PDF

Show description

The subsections on associated components and secondary components describe the tests and studies for establishing suitability and quality control for these types of components. However, the ultimate proof of the suitability of the container closure system and the packaging process is established by full shelf-life stability studies. Every proposed packaging system should be shown to be suitable for its intended use: It should adequately protect the dosage form, it should be compatible with the dosage form, and it should be composed of materials that are considered safe for use with the dosage form and the route of administration.

The type and extent of information that should be provided in an application will depend on the dosage form and the route of administration. For example, the kind of information that should be provided about a packaging system for an injectable dosage form or a drug product for inhalation is often more detailed than that which should be provided about a packaging system for a solid oral dosage form. More detailed information usually should be provided for a liquid-based dosage form than for a powder or a solid, as a liquid-based dosage form is more likely to interact with the packaging components.

DRUG PRODUCTS INTENDED REFRIGERATOR FOR STORAGE Reference Relative Humidity (%) 25 40 25 IN A If the drug product is packaged in a semipermeable container, appropriate information should be provided to assess the extent of water loss. 7). If significant change occurs between 3 and 6 months’ testing at the accelerated storage condition, the proposed shelf life should be based on the real-time data available from the long-term storage condition. , during shipment and handling). This discussion can be supported, if appropriate, by further testing on a single batch of the drug product for a period shorter than 3 months but with more frequent testing than usual.